In unstable coronary artery disease (CAD) it still is a matter of debate which patients should undergo early revascularisation. In the FRISC II study (n=2457) an early invasive strategy was, compared to a primarily non-invasive strategy, associated with reduced mortality and myocardial infarction (MI) rates. However, in this heterogeneous group of patients, tools for an appropriate selection to revascularisation are needed. From the FRISC II study we evaluated the prognosis, the angiographic extent of CAD and the effects of an early invasive strategy in relation to risk variables on admission. The occurrence of ST depression and/or elevated levels of Troponin T were associated with a higher risk for death and MI, more severe CAD and also with a reduction of death or MI by the early invasive strategy. Elevated levels of the inflammatory markers C-reactive protein (CRP) and interleukin-6 (Il-6) were associated with a higher mortality but an unchanged MI rate. Elevated levels of Il-6, but not CRP, identified patients with a large reduction of mortality by the invasive strategy. Age ≥ 70 years, male gender, diabetes, previous MI, ST depression and elevated levels of troponin and markers of inflammation were independently associated with an adverse outcome. The FRISC-score was constructed using these 7 variables. At FRISC-score ≥ 5 an early invasive strategy markedly reduced mortality and MI, at FRISC–score 3-4 death/MI was reduced, whereas in patients with a FRISC-score 0-2 neither mortality nor death/MI was influenced. In unstable CAD, a non-invasive strategy seems justified only for patients at low risk, i.e. FRISC score < 2. In patients with intermediate and high risk, i.e. FRISC-score ≥ 3, an early invasive strategy is recommended.

INTRODUÇÃO: A utilização de medidas diagnósticas e terapêuticas tem impacto significativo na morbidade e mortalidade associadas a síndromes miocárdicas isquêmicas instáveis (SIMI). A quantificação do uso destas medidas permite mensurar a qualidade no atendimento ao paciente por diferentes instituições de saúde, países ou regiões. Dados a respeito da utilização de medidas de desempenho no atendimento a pacientes com SIMI são escassos no Brasil, e a coleta de dados confiáveis a esse respeito é o objetivo do Registro Brasileiro de Síndromes Coronárias Agudas (BRACE). MÉTODOS: BRACE é um registo epidemiológico transversal, observacional de pacientes com SIMI. Para seleção dos hospitais foi adotada a metodologia de \"amostragem por conglomerados\", estratificada por região, característica de ensino (universitário ou não) e entidade mantenedora (público ou privado) para se obter uma imagem representativa de pacientes com SIMI no país. Escore de desempenho que varia de 0 a 100% foi desenvolvido para comparar os parâmetros estudados. As variáveis de desempenho isoladamente e as pontuações do escore foram comparados entre os tipos de instituições e a relação entre a pontuação de desempenho e os desfechos foram avaliados. RESULTADOS: 1.150 pacientes com idade média de 63 anos, 64% do sexo masculino, de 72 hospitais foram incluídos no registro. O escore desempenho médio para a população geral foi de 65,9% ± 20,1%. Instituições de ensino tiveram uma pontuação de desempenho significativamente mais elevada (71,4% ± 16,9%) em comparação com os hospitais não docentes (63,4% ± 21%; p < 0,001). A mortalidade hospitalar foi de 5,2%, e as variáveis que se correlacionaram significativamente e de forma independente com a mortalidade intra-hospitalar foram: idade - por ano (OR = 1,06, 95% IC 1,04-1,09, P < 0,001), doença renal crônica (OR = 3,59 , 95% IC 1,32-9,75, P= 0,012), angioplastia prévia (OR = 0,23, 95% IC 0,07-0,77, P= 0,017) e escore de desempenho - por ponto de aumento (OR = 0,97, 95% IC 0,96-0,98, P < 0,001). CONCLUSÃO: Os dados deste estudo demonstram que o uso de ferramentas de diagnóstico e abordagens terapêuticas para o tratamento das SIMI é distribuído de forma heterogênea e inferior ao ideal no Brasil, e que o escore de desempenho está associado de forma independente a mortalidade intrahospitalar / BACKGROUND: The use of diagnostic and therapeutic tools has a significant impact on morbidity and mortality associated with acute coronary syndromes (ACS). Data about the utilization of ACS performance measures are scarce in Brazil, and improving its reliable collection is an objective of the Brazilian Registry in Acute Coronary syndromEs (BRACE). METHODS: BRACE is a cross-sectional, observational epidemiological registry of ACS patients. Stratified \"cluster sampling\" methodology was adopted to obtain a representative picture of ACS in the country. A performance score varying from 0 to 100 was developed to compare the studied parameters. The performance measures alone and the performance scores were compared between institutions, and the relationship between the performance score and outcomes was evaluated. RESULTS: 1,150 patients median age 63 years, 64% male, from 72 hospitals were included in the registry. The mean performance score for the overall population was 65.9%±20.1%. Teaching institutions had a significantly higher performance score (71.4% ± 16.9%) compared to non-teaching hospitals (63.4% ± 21%; P < 0.001). In-hospital mortality was 5.2%, and the variables that correlated significantly and independently with in-hospital mortality included age - per year (OR=1.06, 95% CI 1.04-1.09, P < 0.001), chronic kidney disease (OR=3.59, 95% CI 1.32-9.75, P=0.012), prior angioplasty (OR=0.23, 95% CI 0.07-0.77, P=0.017) and performance score - per point increase (OR=0.97, 95% CI 0.96-0.98, P < 0.001). CONCLUSION: Data from this study demonstrate that use of diagnostic tools and therapeutic approaches for the management of ACS is heterogeneous and less than ideal in Brazil, and that performance score is independently associated with in-hospital mortality

Introdução: O tratamento da Síndrome Coronária Aguda (SCA) sem supradesnivelamento do segmento ST (SSST) sofreu grandes avanços nos últimos 20 anos, com a introdução de novos medicamentos e intervenções invasivas, que reduziram significativamente os eventos clínicos graves como morte e re(infarto), em curto, médio e longo prazos, a despeito dessa entidade ainda representar uma alta taxa de mortalidade no mundo ocidental. Entre os medicamentos, os inibidores da enzima conversora da angiotensina (IECA) tiveram um papel fundamental, demonstrando redução desses eventos em pacientes com alto risco cardiovascular. Nesse período, as troponinas cardíacas consolidaram-se como os biomarcadores de necrose miocárdica de escolha para o diagnóstico e avaliação prognóstica nesses pacientes, devido às suas altas sensibilidade e especificidade. Objetivo: Determinar o efeito do uso prévio de IECA na mensuração da troponina I cardíaca em pacientes com SCASSST, e avaliar os desfechos clínicos em até 180 dias. Casuística e métodos: Estudo prospectivo, observacional, em um único centro de cardiologia, realizado entre 8 de setembro de 2009 e 10 de outubro de 2010, com 457 pacientes, consecutivamente internados no Pronto-Socorro com SCASSST. Os pacientes deveriam apresentar sintomas isquêmicos agudos, nas últimas 48 horas. Foram excluídos os que apresentassem elevação do segmento ST, ou qualquer alteração confundidora ao ECG, como ritmo de marcapasso, bloqueio de ramo esquerdo ou fibrilação atrial. Foram selecionados para análise exploratória, dados de história clínica, exame físico, eletrocardiográficos e laboratoriais, com ênfase à troponina I cardíaca. As variáveis com nível de significância menor que 10% nesta análise, foram submetidas a um modelo de regressão logística múltipla. Resultados: Na população estudada, observou-se que a idade média era de 62,1 anos (DP=11,04) e 291 pacientes (63,7%) do gênero masculino. Fatores de risco como hipertensão arterial sistêmica (85,3%) e dislipidemia (75,9%) foram os mais prevalentes, além da presença de SCA prévia em 275 (60,2%) pacientes; com 49,5% dos pacientes já submetidos a alguma revascularização prévia (Intervenção Coronária Percutânea(ICP) ou Revascularização do Miocárdio (RM), além de 35,0% de diabéticos. Na avaliação de eventos em 180 dias, ocorreram 28 óbitos (6,1%): 11 por choque cardiogênico, 8 por infarto agudo do miocárdio, 3 por choque séptico, além de outras causas. Foi elaborado um modelo de análise estatística, onde foram analisadas as variáveis que interferiam com a liberação de troponina. Por esse modelo, observou-se que cada 1mg/dL a mais na glicemia de admissão, aumentava a chance da troponina ser maior que 0,5 ng/mL em 0,8% (p=0,0034);o uso de IECA previamente à internação reduzia a chance da troponina ser maior que 0,5 ng/mL em 40,6% (p=0,0482) e a presença de infradesnivelamento do segmento ST igual ou maior a 0,5 mm, em uma ou mais derivações, aumentava a chance da troponina ser maior que 0,5 ng/mL em 2,6 vezes (p=0,0016). A estatística C para este modelo foi de 0,77. Conclusão: Os dados apresentados nesta pesquisa em um centro terciário de cardiologia, mostraram uma correlação inequívoca entre o uso de IECA e a redução do marcador de necrose miocárdica troponina I cardíaca, utilizado como medida qualitativa.Porém, ainda não há dados disponíveis para se afirmar que esta redução poderia levar a um número menor de eventos clínicos graves como morte e re(infarto), no período de 180 dias. / Introduction: The last 20 years have seen great advances in the management of non-ST elevation acute coronary syndrome (NSTE-ACS). The introduction of novel drugs and invasive interventions significantly reduced major clinical events such as death and (re)infarction in the short, medium and long term. Yet, mortality rates remain high in the Western world. Among these drugs, angiotensin-converting enzyme (ACE) inhibitors have played a critical role in reducing these events in patients at high cardiovascular risk. In the meantime, cardiac troponins became firmly established as the myocardial necrosis biomarkers of choice to make the diagnosis and prognosis of these patients, due to their high sensitivity and specificity. Objective: To determine the effect of prior use of ECA inhibitors in serum levels of cardiac troponin I in patients with NSTE-ACS and to assess the clinical outcomes up to 180 days. Patients and methods: This was a prospective, observational study conducted at a single tertiary cardiology center from September 8, 2009 to October 10, 2010 with 457 consecutive patients admitted to the emergency department for NSTE-ACS. Only patients with acute ischemic symptoms within the past 48 hours were included in the study. Those with ST-segment elevation or any confounding ECG factor, such as pacemaker rhythm, left bundle branch block, or atrial fibrillation, were excluded. Study population underwent exploratory analysis, clinical history, physical examination, ECG, and laboratory tests, particularly for cardiac troponin I. Variables with a significance level less then 10% were entered into a multiple logistic regression model. Results: The mean age of the study population was 62.1 years (SD = 11.04), and 291 patients (63.7%) were male. Risk factors such as hypertension (85.3%) and dyslipidemia (75.9%) were the most prevalent, followed by previous ACS in 275 (60.2%) patients; 49.5% of the patients had already undergone previous revascularization procedures (either percutaneous coronary intervention [PCI] or coronary artery bypass grafting [CABG]). Diabetes was present in 35% of the patients. At the 180-day assessment, 28 patients (6.1%) had died: 11 as a result of cardiogenic shock, 8 of acute myocardial infarction, and 3 of septic shock, among other causes. In this study, a statistical model was developed to determine which variables affected troponin release. This model showed that each 1mg/dL increase in admission blood glucose increased the likelihood of troponin being higher than 0.5 ng/mL by 0.8% (p=0.0034); the use of ACE inhibitors prior to admission reduced the likelihood of troponin being higher than 0.5 ng/mL by 40.6% (p=0.0482), and the presence of ST-segment depression >= 0.5 mm in one or more ECG leads increased 2.6 times the likelihood of troponin being higher than 0.5 ng/mL (p=0.0016). The C-statistic for this model was 0.77. Conclusion: The data from this study conducted at a tertiary cardiology center show an unequivocal relationship between the use of ACE inhibitors and decreased levels of cardiac troponin I, a biomarker of myocardial necrosis used as a qualitative measure. However, there is no available data to determine whether or not this decrease would result in a lower number of major clinical events, such as death and re(infarction) within 180 days.

INTRODUÇÃO: A proteína C-reativa de alta sensibilidade (PCR-as) é comumente utilizada na prática clínica para avaliar o risco cardiovascular. O seio coronário (SC) é considerado o local ideal para estudos de marcadores inflamatórios e circulação coronária, até o momento. A correlação entre os níveis séricos de PCR-as (valores absolutos) periférico versus (vs.) central ainda não foi feita. Avaliou-se a correlação entre os níveis séricos de PCR-as (mg/L) em veia periférica do antebraço esquerdo (VPAE) vs. SC, em pacientes portadores de doença arterial coronária (DAC) aterosclerótica com diagnóstico de angina estável (AE) ou angina instável (AI). Avaliou-se, também, se os níveis de PCR-as na VPAE e no SC diferem na AE e AI. MÉTODOS e RESULTADOS: 40 pacientes com DAC e estenose >= 70 % do diâmetro da luz vascular em uma das principais artérias coronárias foram incluídos no estudo e classificados em AE (n = 20) e, AI (n = 20). Coletaram-se amostras de sangue simultaneamente na VPAE e no SC, antes da angiografia coronária. A média dos níveis séricos absolutos de PCR-as na VPAE nos pacientes com AE foi de 2,97 ± 2,66, log 0,53 ± 1,24 e, com AI foi de 3,04 ± 3,29, log 0,67 ± 0,94, p = 0,689; e no SC, na AE foi de 2,71 ± 2,46, log 0,46 ± 1,18 e na AI, foi de 2,65 ± 3,08, log 0,41 ± 0,97, p = 0,898 e, portanto, não foram observadas diferenças significativas. A análise de correlação entre os níveis séricos de PCR-as em VPAE vs. SC mostrou uma forte correlação linear tanto para AE (r = 0,993, p < 0,001), para AI (r = 0,976, p < 0,001) e em toda amostra (r = 0,985, p < 0,001). CONCLUSÃO: Os nossos dados sugeriram uma forte correlação linear entre os níveis séricos de PCR-as na VPAE vs. SC na AE e AI; e esses níveis na VPAE e no SC na AE e AI foram semelhantes e não revelaram diferentes influências biológicas / BACKGROUND: The high-sensitivity C-reactive protein (hs-CRP) is commonly used in clinical practice to assess cardiovascular risk. The coronary sinus (CS) is considered the ideal location for studies of inflammatory markers and coronary circulation, until the moment. The correlation between peripheral versus (vs.) central serum levels of hs-CRP (absolute values) has not been done. We evaluated the correlation between serum levels of hs-CRP (mg/L) in the left forearm peripheral vein (LFPV) vs. CS in patients with atherosclerotic coronary artery disease (CAD) and diagnosis of stable angina (SA) or unstable angina (UA). We also evaluated whether the hs-CRP levels in LFPV and CS differ in SA and UA. METHODS and RESULTS: 40 patients with CAD and >= 70 % stenosis of the diameter of the vascular lumen in one of the main coronary arteries were included in the study and, classified into SA (n = 20) and, UA (n = 20). Blood samples from in the LFPV and CS were simultaneously collected before coronary angiography. The mean serum levels of hs-CRP in LFPV in the patients with SA was 2.97 ± 2.66, log 0.53 ± 1.24 and, in the UA was 3.04 ± 3.29, log 0.67 ± 0.94, p = 0.689. In CS in SA, it was 2.71 ± 2.46, log 0.46 ± 1.18 and in UA it was 2.65 ± 3.08, log 0.41 ± 0.97, p = 0.898; therefore, no significant differences were observed. The correlation analysis between the serum levels of hs-CRP in LFPV vs. CS showed a strong linear correlation in both for SA (r = 0.993, p < 0.001), for UA (r = 0.976, p < 0.001) and in the whole sample (r = 0.985, p < 0.001). CONCLUSIONS: Our data suggested that in SA as well as in UA there was a strong linear correlation between the serum levels of hs-CRP in LFPV vs. CS and, these levels in VPAE and SC in AE and AI were similar and did not reveal different biological influences

<p>In patients with unstable coronary artery disease (CAD) biochemical markers are emerging as useful tools in clinical management. In this thesis we studied the use of markers of low-density lipoprotein (LDL) oxidation and renal function.</p><p>Our study populations consisted of unstable CAD patients included in the Fast Revascularisation during Instability in Coronary artery disease (FRISC)-II trial and healthy controls. Patients were followed for 2 years regarding death and myocardial infarction (MI).</p><p>Using receiver operating characteristic curve analysis, we found that oxidized low-density lipoprotein (OxLDL), especially when combined with high-density lipoprotein, compared to traditionally measured lipids/lipoproteins, and a new lipoprotein marker, lipoprotein associated-phospholipase A2, was better at discriminating between healthy controls and CAD patients. In patients, OxLDL was found to be an independent prognostic marker associated with an increased risk of MI, of particular use in patients with no evidence of myocardial necrosis. </p><p>In our study on the effects of an early invasive treatment strategy in unstable CAD patients with mild to moderate renal dysfunction (i.e. creatinine clearance <90mL/min) we found that in patients randomized to invasive treatment, the rates of death/MI and MI alone were significantly lower than in patients randomized to non-invasive treatment. In patients treated invasively, no detrimental effects were seen on renal function at follow-up at 6 months. </p><p>In healthy controls, we investigated new markers of renal (cystatin C) and cardio-renal function (N-terminal probrain natriuretic peptide, [NT-proBNP]) regarding reference levels and physiological determinants. We found that cystatin C is influenced by age whereas NT-proBNP is influenced by age and gender.</p><p>Our studies suggest that OxLDL and renal dysfunction are associated with a poor prognosis in unstable CAD patients and that these markers demonstrate potential for clinical use. In the search for new markers related to renal function we have contributed with reference levels of cystatin C and NT-proBNP. </p>

In patients with unstable coronary artery disease (CAD) biochemical markers are emerging as useful tools in clinical management. In this thesis we studied the use of markers of low-density lipoprotein (LDL) oxidation and renal function. Our study populations consisted of unstable CAD patients included in the Fast Revascularisation during Instability in Coronary artery disease (FRISC)-II trial and healthy controls. Patients were followed for 2 years regarding death and myocardial infarction (MI). Using receiver operating characteristic curve analysis, we found that oxidized low-density lipoprotein (OxLDL), especially when combined with high-density lipoprotein, compared to traditionally measured lipids/lipoproteins, and a new lipoprotein marker, lipoprotein associated-phospholipase A2, was better at discriminating between healthy controls and CAD patients. In patients, OxLDL was found to be an independent prognostic marker associated with an increased risk of MI, of particular use in patients with no evidence of myocardial necrosis. In our study on the effects of an early invasive treatment strategy in unstable CAD patients with mild to moderate renal dysfunction (i.e. creatinine clearance &lt;90mL/min) we found that in patients randomized to invasive treatment, the rates of death/MI and MI alone were significantly lower than in patients randomized to non-invasive treatment. In patients treated invasively, no detrimental effects were seen on renal function at follow-up at 6 months. In healthy controls, we investigated new markers of renal (cystatin C) and cardio-renal function (N-terminal probrain natriuretic peptide, [NT-proBNP]) regarding reference levels and physiological determinants. We found that cystatin C is influenced by age whereas NT-proBNP is influenced by age and gender. Our studies suggest that OxLDL and renal dysfunction are associated with a poor prognosis in unstable CAD patients and that these markers demonstrate potential for clinical use. In the search for new markers related to renal function we have contributed with reference levels of cystatin C and NT-proBNP.

Introdução: O tratamento da Síndrome Coronária Aguda (SCA) sem supradesnivelamento do segmento ST (SSST) sofreu grandes avanços nos últimos 20 anos, com a introdução de novos medicamentos e intervenções invasivas, que reduziram significativamente os eventos clínicos graves como morte e re(infarto), em curto, médio e longo prazos, a despeito dessa entidade ainda representar uma alta taxa de mortalidade no mundo ocidental. Entre os medicamentos, os inibidores da enzima conversora da angiotensina (IECA) tiveram um papel fundamental, demonstrando redução desses eventos em pacientes com alto risco cardiovascular. Nesse período, as troponinas cardíacas consolidaram-se como os biomarcadores de necrose miocárdica de escolha para o diagnóstico e avaliação prognóstica nesses pacientes, devido às suas altas sensibilidade e especificidade. Objetivo: Determinar o efeito do uso prévio de IECA na mensuração da troponina I cardíaca em pacientes com SCASSST, e avaliar os desfechos clínicos em até 180 dias. Casuística e métodos: Estudo prospectivo, observacional, em um único centro de cardiologia, realizado entre 8 de setembro de 2009 e 10 de outubro de 2010, com 457 pacientes, consecutivamente internados no Pronto-Socorro com SCASSST. Os pacientes deveriam apresentar sintomas isquêmicos agudos, nas últimas 48 horas. Foram excluídos os que apresentassem elevação do segmento ST, ou qualquer alteração confundidora ao ECG, como ritmo de marcapasso, bloqueio de ramo esquerdo ou fibrilação atrial. Foram selecionados para análise exploratória, dados de história clínica, exame físico, eletrocardiográficos e laboratoriais, com ênfase à troponina I cardíaca. As variáveis com nível de significância menor que 10% nesta análise, foram submetidas a um modelo de regressão logística múltipla. Resultados: Na população estudada, observou-se que a idade média era de 62,1 anos (DP=11,04) e 291 pacientes (63,7%) do gênero masculino. Fatores de risco como hipertensão arterial sistêmica (85,3%) e dislipidemia (75,9%) foram os mais prevalentes, além da presença de SCA prévia em 275 (60,2%) pacientes; com 49,5% dos pacientes já submetidos a alguma revascularização prévia (Intervenção Coronária Percutânea(ICP) ou Revascularização do Miocárdio (RM), além de 35,0% de diabéticos. Na avaliação de eventos em 180 dias, ocorreram 28 óbitos (6,1%): 11 por choque cardiogênico, 8 por infarto agudo do miocárdio, 3 por choque séptico, além de outras causas. Foi elaborado um modelo de análise estatística, onde foram analisadas as variáveis que interferiam com a liberação de troponina. Por esse modelo, observou-se que cada 1mg/dL a mais na glicemia de admissão, aumentava a chance da troponina ser maior que 0,5 ng/mL em 0,8% (p=0,0034);o uso de IECA previamente à internação reduzia a chance da troponina ser maior que 0,5 ng/mL em 40,6% (p=0,0482) e a presença de infradesnivelamento do segmento ST igual ou maior a 0,5 mm, em uma ou mais derivações, aumentava a chance da troponina ser maior que 0,5 ng/mL em 2,6 vezes (p=0,0016). A estatística C para este modelo foi de 0,77. Conclusão: Os dados apresentados nesta pesquisa em um centro terciário de cardiologia, mostraram uma correlação inequívoca entre o uso de IECA e a redução do marcador de necrose miocárdica troponina I cardíaca, utilizado como medida qualitativa.Porém, ainda não há dados disponíveis para se afirmar que esta redução poderia levar a um número menor de eventos clínicos graves como morte e re(infarto), no período de 180 dias. / Introduction: The last 20 years have seen great advances in the management of non-ST elevation acute coronary syndrome (NSTE-ACS). The introduction of novel drugs and invasive interventions significantly reduced major clinical events such as death and (re)infarction in the short, medium and long term. Yet, mortality rates remain high in the Western world. Among these drugs, angiotensin-converting enzyme (ACE) inhibitors have played a critical role in reducing these events in patients at high cardiovascular risk. In the meantime, cardiac troponins became firmly established as the myocardial necrosis biomarkers of choice to make the diagnosis and prognosis of these patients, due to their high sensitivity and specificity. Objective: To determine the effect of prior use of ECA inhibitors in serum levels of cardiac troponin I in patients with NSTE-ACS and to assess the clinical outcomes up to 180 days. Patients and methods: This was a prospective, observational study conducted at a single tertiary cardiology center from September 8, 2009 to October 10, 2010 with 457 consecutive patients admitted to the emergency department for NSTE-ACS. Only patients with acute ischemic symptoms within the past 48 hours were included in the study. Those with ST-segment elevation or any confounding ECG factor, such as pacemaker rhythm, left bundle branch block, or atrial fibrillation, were excluded. Study population underwent exploratory analysis, clinical history, physical examination, ECG, and laboratory tests, particularly for cardiac troponin I. Variables with a significance level less then 10% were entered into a multiple logistic regression model. Results: The mean age of the study population was 62.1 years (SD = 11.04), and 291 patients (63.7%) were male. Risk factors such as hypertension (85.3%) and dyslipidemia (75.9%) were the most prevalent, followed by previous ACS in 275 (60.2%) patients; 49.5% of the patients had already undergone previous revascularization procedures (either percutaneous coronary intervention [PCI] or coronary artery bypass grafting [CABG]). Diabetes was present in 35% of the patients. At the 180-day assessment, 28 patients (6.1%) had died: 11 as a result of cardiogenic shock, 8 of acute myocardial infarction, and 3 of septic shock, among other causes. In this study, a statistical model was developed to determine which variables affected troponin release. This model showed that each 1mg/dL increase in admission blood glucose increased the likelihood of troponin being higher than 0.5 ng/mL by 0.8% (p=0.0034); the use of ACE inhibitors prior to admission reduced the likelihood of troponin being higher than 0.5 ng/mL by 40.6% (p=0.0482), and the presence of ST-segment depression >= 0.5 mm in one or more ECG leads increased 2.6 times the likelihood of troponin being higher than 0.5 ng/mL (p=0.0016). The C-statistic for this model was 0.77. Conclusion: The data from this study conducted at a tertiary cardiology center show an unequivocal relationship between the use of ACE inhibitors and decreased levels of cardiac troponin I, a biomarker of myocardial necrosis used as a qualitative measure. However, there is no available data to determine whether or not this decrease would result in a lower number of major clinical events, such as death and re(infarction) within 180 days.

INTRODUÇÃO: A proteína C-reativa de alta sensibilidade (PCR-as) é comumente utilizada na prática clínica para avaliar o risco cardiovascular. O seio coronário (SC) é considerado o local ideal para estudos de marcadores inflamatórios e circulação coronária, até o momento. A correlação entre os níveis séricos de PCR-as (valores absolutos) periférico versus (vs.) central ainda não foi feita. Avaliou-se a correlação entre os níveis séricos de PCR-as (mg/L) em veia periférica do antebraço esquerdo (VPAE) vs. SC, em pacientes portadores de doença arterial coronária (DAC) aterosclerótica com diagnóstico de angina estável (AE) ou angina instável (AI). Avaliou-se, também, se os níveis de PCR-as na VPAE e no SC diferem na AE e AI. MÉTODOS e RESULTADOS: 40 pacientes com DAC e estenose >= 70 % do diâmetro da luz vascular em uma das principais artérias coronárias foram incluídos no estudo e classificados em AE (n = 20) e, AI (n = 20). Coletaram-se amostras de sangue simultaneamente na VPAE e no SC, antes da angiografia coronária. A média dos níveis séricos absolutos de PCR-as na VPAE nos pacientes com AE foi de 2,97 ± 2,66, log 0,53 ± 1,24 e, com AI foi de 3,04 ± 3,29, log 0,67 ± 0,94, p = 0,689; e no SC, na AE foi de 2,71 ± 2,46, log 0,46 ± 1,18 e na AI, foi de 2,65 ± 3,08, log 0,41 ± 0,97, p = 0,898 e, portanto, não foram observadas diferenças significativas. A análise de correlação entre os níveis séricos de PCR-as em VPAE vs. SC mostrou uma forte correlação linear tanto para AE (r = 0,993, p < 0,001), para AI (r = 0,976, p < 0,001) e em toda amostra (r = 0,985, p < 0,001). CONCLUSÃO: Os nossos dados sugeriram uma forte correlação linear entre os níveis séricos de PCR-as na VPAE vs. SC na AE e AI; e esses níveis na VPAE e no SC na AE e AI foram semelhantes e não revelaram diferentes influências biológicas / BACKGROUND: The high-sensitivity C-reactive protein (hs-CRP) is commonly used in clinical practice to assess cardiovascular risk. The coronary sinus (CS) is considered the ideal location for studies of inflammatory markers and coronary circulation, until the moment. The correlation between peripheral versus (vs.) central serum levels of hs-CRP (absolute values) has not been done. We evaluated the correlation between serum levels of hs-CRP (mg/L) in the left forearm peripheral vein (LFPV) vs. CS in patients with atherosclerotic coronary artery disease (CAD) and diagnosis of stable angina (SA) or unstable angina (UA). We also evaluated whether the hs-CRP levels in LFPV and CS differ in SA and UA. METHODS and RESULTS: 40 patients with CAD and >= 70 % stenosis of the diameter of the vascular lumen in one of the main coronary arteries were included in the study and, classified into SA (n = 20) and, UA (n = 20). Blood samples from in the LFPV and CS were simultaneously collected before coronary angiography. The mean serum levels of hs-CRP in LFPV in the patients with SA was 2.97 ± 2.66, log 0.53 ± 1.24 and, in the UA was 3.04 ± 3.29, log 0.67 ± 0.94, p = 0.689. In CS in SA, it was 2.71 ± 2.46, log 0.46 ± 1.18 and in UA it was 2.65 ± 3.08, log 0.41 ± 0.97, p = 0.898; therefore, no significant differences were observed. The correlation analysis between the serum levels of hs-CRP in LFPV vs. CS showed a strong linear correlation in both for SA (r = 0.993, p < 0.001), for UA (r = 0.976, p < 0.001) and in the whole sample (r = 0.985, p < 0.001). CONCLUSIONS: Our data suggested that in SA as well as in UA there was a strong linear correlation between the serum levels of hs-CRP in LFPV vs. CS and, these levels in VPAE and SC in AE and AI were similar and did not reveal different biological influences

Introduction: Acute coronary syndromes (ACS) belong to cardiovascular diseases and contribute significantly to mortality, morbidity and disability in developed countries. Therefore the aim of current therapy is to reduce the risk of subsequent complications, including early death, and to increase patients' quality of life. For successful therapy it is necessary to follow regimen and dietary principles which are along with pharmacotherapy an integral part of treatment. Therefore sufficient knowledge of these principles by patients is a basic precondition for their successful treatment. Objectives: The aim of the diploma thesis was to assess dietary and regime knowledge in patients diagnosed with ACS. The specific objectives were: to determine an effect of sex or previous education on the knowledge; to describe patients' dietary habits; to specify their knowledge of nutrition; and to identify which knowledge is the most deficient. Methods: The research was carried out as a questionnaire survey. The questionnaire was compiled directly for the purposes of this thesis and was approved by the VFN Ethics Committee for use in inpatient wards at II. and III. internal clinics and at the Coronary unit of II. internal clinics of VFN. A total of 80 patients diagnosed with ACS were included in the study....

Acute coronary syndrome (ACS) refers to a group of clinical conditions caused by myocardial ischemia including unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI), and ST-segmcnt elevation myocardial infarction (STEMI). Appropriate and accurate diagnosis has life-saving implications and requires a quick but thorough evaluation of the patient's history, physical examination, electrocardiogram, radiographic studies, and cardiac biomarkers. The management of patients with suspected or confirmed ACS continues to evolve as new evidence from clinical trials is considered and as new technology becomes available to both primary care physicians and cardiologists. Low- and intermediate-risk patients have frequently been managed in a chest pain center or in the emergency department. While stress testing with or without radionuclide imaging is the most common evaluation method, a CT angiogram is sometimes substituted High-risk patients are often managed with an early invasive strategy involving left heart catheterization with a goal of prompt revascularization of at-risk, viable myocardium. With the increased availability of cardiac catheterization facilities, patients with STEMI are more commonly being managed with primary percutaneous coronary intervention, although thrombolysis is still used where such facilities are not immediately available. This article provides primary care physicians with a concise review of the pathophysiology, clinical evaluation, and management of ACS based on the best available evidence in 2008.